Table 1.
Baseline characteristics of all patients (N = 28,628).
Table 2.
Baseline prescription of guideline-recommended therapies in patients with congestive heart failure or vascular disease*.
Table 3.
Monotherapy and combinations of guideline-recommended therapies prescribed for patients with congestive heart failure or vascular disease.
Table 4.
Two-year event rates including additional outcomes.
Table 5.
Breakdown of primary outcomes by type of event at 2-year follow-up.
Fig 1.
Adjusted hazard ratios for 2-year outcomes according to baseline characteristics and anticoagulant treatment: (A) all-cause mortality; (B) stroke/systemic embolism; (C) major bleeding. ‘Anticoagulant treatment’ includes both vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. For race, ‘Asian’ includes Asian (not Chinese) and Chinese, and ‘other’ includes Afro-Caribbean, mixed/other, and unwilling to declare/not recorded. Reference groups, from top: <65 years, men, Caucasian/Hispanic/Latino, never smoker, no history of disease (for diabetes, hypertension, stroke/TIA/SE, history of bleeding, cardiac failure, vascular disease, and renal disease), no AC treatment, paroxysmal AF, alcohol abstinence. Hazard ratios were adjusted for all variables in the model. AC, anticoagulant; AF, atrial fibrillation; CI, confidence interval; HR, hazard ratio; SE, systemic embolism; TIA, transient ischaemic attack.
Table 6.
Crude event rates during 2-year follow-up according to CHA2DS2-VASc score.
Fig 2.
Relationships between variables and clinical outcomes during 2-year follow-up.
Key to symbols used: upwards arrow indicates increased risk, downwards arrow indicates reduced risk, double-headed arrow indicates no change in risk. AF, atrial fibrillation; SE, systemic embolism; TIA, transient ischaemic attack.